• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>MedImmune

MedImmune

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. ASTRAZENECA’S COMBINATION OF DURVALUMAB WITH TREMELIMUMAB SHOWS CLINICAL ACTIVITY IN NON-SMALL CELL LUNG CANCER IRRESPECTIVE OF PD-L1 STATUS

    ASTRAZENECA’S COMBINATION OF DURVALUMAB WITH TREMELIMUMAB SHOWS CLINICAL ACTIVITY IN NON-SMALL CELL LUNG CANCER IRRESPECTIVE OF PD-L1 STATUS

  2. Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015 - Research and Markets

    Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015 - Research and Markets

  3. Osiris Therapeutics Announces Leadership Transition

    Osiris Therapeutics Announces Leadership Transition

  4. APR 16-17: USA Science & Engineering Festival Promotes STEM with 3,000 Hands-on Activities, Shows and Science Celebs

    APR 16-17: USA Science & Engineering Festival Promotes STEM with 3,000 Hands-on Activities, Shows and Science Celebs

  5. World Small-Cell Lung Cancer Therapeutic Development Pipeline Review, H2 2015 - Research and Markets

    World Small-Cell Lung Cancer Therapeutic Development Pipeline Review, H2 2015 - Research and Markets

  6. Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma

    Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma

  7. H5N1 Infection (Avian Influenza) Therapeutics Development Pipeline Review, H2 2015 - Research and Markets

    H5N1 Infection (Avian Influenza) Therapeutics Development Pipeline Review, H2 2015 - Research and Markets

  8. Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015 - Research and Markets

    Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015 - Research and Markets

  9. Aldevron Appoints Dr. James Brown as Vice President of Corporate Development

    Aldevron Appoints Dr. James Brown as Vice President of Corporate Development

  10. AstraZeneca and Moderna Therapeutics Announce New Collaboration to Co-Develop and Co-Commercialize Immuno-Oncology mRNA Therapeutics™

    AstraZeneca and Moderna Therapeutics Announce New Collaboration to Co-Develop and Co-Commercialize Immuno-Oncology mRNA Therapeutics™

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.